- Home
- BTAI vs FTHM Comparison
BTAI vs FTHM Comparison
Compare BTAI & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTAI | FTHM |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 31.5M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTAI | FTHM |
|---|---|---|
| Price | $1.47 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.25 | $2.50 |
| AVG Volume (30 Days) | ★ 1.2M | 78.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.21 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $335,184,000.00 |
| Revenue This Year | N/A | $30.07 |
| Revenue Next Year | $261.81 | $14.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $0.65 |
| 52 Week High | $8.08 | $3.37 |
Technical Indicators
Market Signals| Indicator | BTAI | FTHM |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 39.69 |
| Support Level | $1.44 | $0.70 |
| Resistance Level | $2.22 | $1.49 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 2.63 | 30.03 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.